As of March 23, 2026, Crinetics Pharmaceuticals's top three insider holders are Advisors Llc Perceptive (TenPercentOwner, 5.32Mn shares), Richard Scott Struthers (President Ceo, 426.76K shares), Ajay Madan (Chief Development Officer, 177.00K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Advisors Llc Perceptive | 0 | 5,321,032 | 18 Apr, 2022 | |
| Richard Scott Struthers | President Ceo | 404,778 | 0 | 18 Mar, 2026 |
| Ajay Madan | Chief Development Officer | 176,995 | 0 | 02 Mar, 2022 |
| Stephen F. Betz | Chief Scientific Officer | 137,101 | 0 | 18 Mar, 2026 |
| Wendall Wierenga | 116,146 | 0 | 13 Jun, 2025 | |
| Jeff E. Knight | Chief Operating Officer | 112,018 | 0 | 18 Mar, 2026 |
| Marc Wilson | Cfo | 111,092 | 0 | 30 Sep, 2024 |
| Richard Scott Struthers | President Ceo | 0 | 106,000 | 30 Sep, 2025 |
| Tobin Schilke | Chief Financial Officer | 78,121 | 0 | 04 Mar, 2026 |
| Dana Pizzuti | Chief Med And Dev Officer | 66,837 | 0 | 03 Dec, 2025 |
| Alan Seth Krasner | Chief Medical Officer | 43,210 | 0 | 19 Oct, 2023 |
| Isabel Kalofonos | Chief Commercial Officer | 34,834 | 0 | 25 Feb, 2026 |
| James Hassard | Chief Commercial Officer | 29,259 | 0 | 09 Jul, 2024 |
| Matthew K Fust | 22,836 | 0 | 30 Sep, 2025 | |
| Caren Deardorf | 16,300 | 0 | 13 Jun, 2025 | |
| Coelho Rogerio Vivaldi | 16,300 | 0 | 13 Mar, 2026 | |
| Weston Nichols | 16,300 | 0 | 13 Jun, 2025 | |
| Stephanie Okey | 13,300 | 0 | 04 Mar, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 16 Mar, 2026 | Stephen F. Betz | Common Stock | D | 6,371 | $37.11 | 141,342 | D | S |
| 16 Mar, 2026 | Richard Scott Struthers | Common Stock | D | 13,196 | $37.11 | 413,563 | D | S |
| 16 Mar, 2026 | Jeff E. Knight | Common Stock | D | 5,950 | $37.11 | 115,979 | D | S |
| 16 Mar, 2026 | Richard Scott Struthers | Common Stock | D | 8,785 | $37.77 | 404,778 | D | S |
| 16 Mar, 2026 | Jeff E. Knight | Common Stock | D | 3,961 | $37.77 | 112,018 | D | S |
| 16 Mar, 2026 | Stephen F. Betz | Common Stock | D | 4,241 | $37.77 | 137,101 | D | S |
| 12 Mar, 2026 | Coelho Rogerio Vivaldi | Common Stock | D | 4,477 | $36.08 | 16,823 | D | S |
| 12 Mar, 2026 | Coelho Rogerio Vivaldi | Common Stock | D | 523 | $36.77 | 16,300 | D | S |
| 03 Mar, 2026 | Stephanie Okey | Common Stock | D | 3,000 | $39.67 | 13,300 | D | S |
| 03 Mar, 2026 | Tobin Schilke | Common Stock | D | 6,713 | $39.67 | 78,121 | D | S |
| 23 Feb, 2026 | Stephen F. Betz | Common Stock | A | 30,000 | $0.00 | 147,713 | D | A |
| 23 Feb, 2026 | Tobin Schilke | Common Stock | A | 32,000 | $0.00 | 84,834 | D | A |
| 23 Feb, 2026 | Isabel Kalofonos | Common Stock | A | 34,000 | $0.00 | 34,834 | D | A |
| 23 Feb, 2026 | Richard Scott Struthers | Common Stock | A | 62,000 | $0.00 | 426,759 | D | A |
| 23 Feb, 2026 | Jeff E. Knight | Common Stock | A | 34,000 | $0.00 | 121,929 | D | A |
| 23 Feb, 2026 | Tobin Schilke | Stock Option (Right to Buy) | A | 50,000 | $0.00 | 50,000 | D | A |
| 23 Feb, 2026 | Jeff E. Knight | Stock Option (Right to Buy) | A | 55,000 | $0.00 | 55,000 | D | A |
| 23 Feb, 2026 | Stephen F. Betz | Stock Option (Right to Buy) | A | 47,000 | $0.00 | 47,000 | D | A |
| 23 Feb, 2026 | Isabel Kalofonos | Stock Option (Right to Buy) | A | 55,000 | $0.00 | 55,000 | D | A |
| 23 Feb, 2026 | Richard Scott Struthers | Stock Option (Right to Buy) | A | 228,000 | $0.00 | 228,000 | D | A |